A Stable CHO K1 Cell Line For Producing Recombinant Monoclonal ...

Full text links CiteDisplay options Display options Format AbstractPubMedPMID

Abstract

Monoclonal antibodies (mAbs) are one of the most significant molecules in protein therapeutics. They are employed in the field of immunology, oncology and organ transplant. They have been also been employed for alleviating several bacterial and viral infections. Moreover, they have revolutionized the area of targeted therapy and improved the quality of treatments, as compared to other cytotoxic drugs and therapies. mAbs bind to specific molecules on the antigen and exhibit specificity towards that molecule, i.e. epitope. Thus, mAbs have immense opportunity to be explored for personalized therapy. The introduction of targeted mAb-based therapeutics has promoted many important scientific achievements in rheumatology. This has warranted additional investigations for developing newer mAb producing clones, to supplement the limited industrial production of certain mAb therapeutics. In this investigation, an integrative approach comprising optimized expression, selection and expansion was adopted to develop a mammalian cell line expressing mAb against TNF-α.The resulting stable clone is anticipated to serve as an economic alternative to the industrial clones, especially for research purposes. The clone was constructed for development of biosimilar of the highly valued therapeutic antibody, Humira.

Keywords: Mammalian cell line; Monoclonal antibodies; Protein therapeutics; Stable clone; TNF-α.

© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

PubMed Disclaimer

References

1. 1. Gronemeyer, P., Ditz, R., & Strube, J. (2014). Trends in upstream and downstream process development for antibody manufacturing. Bioengineering, 1(4), 188–212 - DOI
2. 1. Gupta, K., et al. (2019). Vector-related stratagems for enhanced monoclonal antibody production in mammalian cells. Biotechnology Advances
3. 1. Chames, P., et al. (2009). Therapeutic antibodies: Successes, limitations and hopes for the future. British Journal of Pharmacology, 157(2), 220–233 - DOI
4. 1. Voronina, E., et al. (2016). Design of a stable cell line producing a recombinant monoclonal anti-TNFα antibody based on a CHO cell line. Springerplus, 5(1), 1584 - DOI
5. 1. Alonso-Ruiz, A., et al. (2008). Tumor necrosis factor alpha drugs in rheumatoid arthritis: Systematic review and metaanalysis of efficacy and safety. BMC Musculoskeletal Disorders, 9(1), 52 - DOI

Show all 24 references

MeSH terms

• Adalimumab / biosynthesis* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Adalimumab / genetics Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Adalimumab / immunology Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Animals Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Antibody-Dependent Cell Cytotoxicity / genetics Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Antirheumatic Agents / immunology* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Antirheumatic Agents / metabolism Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Biological Assay Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• CHO Cells Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Cricetulus Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Gene Expression Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Humans Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Plasmids / chemistry Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Plasmids / metabolism* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Recombinant Proteins / biosynthesis Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Recombinant Proteins / genetics Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Recombinant Proteins / immunology Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Tumor Necrosis Factor-alpha / antagonists & inhibitors* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Tumor Necrosis Factor-alpha / genetics Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Tumor Necrosis Factor-alpha / immunology Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search

Substances

• Antirheumatic Agents Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Recombinant Proteins Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Tumor Necrosis Factor-alpha Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Adalimumab Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search

Grants and funding

• 3/1/3/JRF-2015/HRD-LS/29/31232/85/Indian Council of Medical Research

LinkOut - more resources

• Full Text Sources

  • Springer

• Other Literature Sources

  • The Lens - Patent Citations Database